DE69420053D1 - Neuroprotektive chroman verbindungen - Google Patents

Neuroprotektive chroman verbindungen

Info

Publication number
DE69420053D1
DE69420053D1 DE69420053T DE69420053T DE69420053D1 DE 69420053 D1 DE69420053 D1 DE 69420053D1 DE 69420053 T DE69420053 T DE 69420053T DE 69420053 T DE69420053 T DE 69420053T DE 69420053 D1 DE69420053 D1 DE 69420053D1
Authority
DE
Germany
Prior art keywords
pct
chroman
neuroprotective
connections
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69420053T
Other languages
English (en)
Other versions
DE69420053T2 (de
Inventor
Todd Butler
Bertrand Chenard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69420053D1 publication Critical patent/DE69420053D1/de
Publication of DE69420053T2 publication Critical patent/DE69420053T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69420053T 1994-01-31 1994-11-21 Neuroprotektive chroman verbindungen Expired - Fee Related DE69420053T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31
PCT/IB1994/000365 WO1995020587A1 (en) 1994-01-31 1994-11-21 Neuroprotective chroman compounds

Publications (2)

Publication Number Publication Date
DE69420053D1 true DE69420053D1 (de) 1999-09-16
DE69420053T2 DE69420053T2 (de) 1999-11-25

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69420053T Expired - Fee Related DE69420053T2 (de) 1994-01-31 1994-11-21 Neuroprotektive chroman verbindungen

Country Status (27)

Country Link
US (1) US5744483A (de)
EP (1) EP0741724B1 (de)
JP (1) JP2866743B2 (de)
CN (1) CN1048247C (de)
AT (1) ATE183184T1 (de)
AU (1) AU684568B2 (de)
BR (2) BR9408506A (de)
CA (1) CA2182101C (de)
CO (1) CO4230161A1 (de)
CZ (1) CZ286757B6 (de)
DE (1) DE69420053T2 (de)
DK (1) DK0741724T3 (de)
EG (1) EG20672A (de)
ES (1) ES2134361T3 (de)
FI (1) FI113769B (de)
GR (1) GR3031356T3 (de)
HU (1) HU221633B1 (de)
IL (1) IL112415A (de)
MY (1) MY111623A (de)
NO (1) NO309190B1 (de)
NZ (1) NZ275151A (de)
PE (1) PE43795A1 (de)
PL (1) PL179448B1 (de)
RU (1) RU2126404C1 (de)
TW (1) TW449591B (de)
WO (1) WO1995020587A1 (de)
ZA (1) ZA95692B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509839A (ja) * 1995-09-15 1999-08-31 ファイザー・インコーポレーテッド 薬剤活性を有するフェノール誘導体
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
EP1674087A1 (de) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
KR100984897B1 (ko) 2005-11-03 2010-10-01 에프. 호프만-라 로슈 아게 5-ｈｔ6 억제제로서 아릴설포닐 크로만
PE20071321A1 (es) * 2006-01-20 2007-12-29 Schering Corp Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
EP2522647B1 (de) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Verfahren zum Trennen von chiralen Isomeren von Chromverbindungen und ihre Derivate und Vorläufer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (de) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE23718T1 (de) * 1981-09-25 1986-12-15 Beecham Group Plc Benzopyran-verbindungen mit pharmazeutischer wirkung.
EP0093534A1 (de) * 1982-04-28 1983-11-09 Beecham Group Plc Chromanolen
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
US5356905A (en) * 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
CO4230161A1 (es) 1995-10-19
IL112415A (en) 1999-07-14
MY111623A (en) 2000-09-27
NO963186L (no) 1996-07-30
NZ275151A (en) 1998-02-26
US5744483A (en) 1998-04-28
CZ286757B6 (en) 2000-06-14
TW449591B (en) 2001-08-11
BR9500380A (pt) 1995-10-17
WO1995020587A1 (en) 1995-08-03
CZ225696A3 (en) 1997-01-15
CN1142825A (zh) 1997-02-12
PL315681A1 (en) 1996-11-25
ES2134361T3 (es) 1999-10-01
EP0741724A1 (de) 1996-11-13
ZA95692B (en) 1996-07-30
EP0741724B1 (de) 1999-08-11
ATE183184T1 (de) 1999-08-15
DE69420053T2 (de) 1999-11-25
CN1048247C (zh) 2000-01-12
DK0741724T3 (da) 1999-12-20
NO309190B1 (no) 2000-12-27
FI950403A (fi) 1995-08-01
HU9602100D0 (en) 1996-09-30
JP2866743B2 (ja) 1999-03-08
NO963186D0 (no) 1996-07-30
IL112415A0 (en) 1995-03-30
PE43795A1 (es) 1995-12-09
GR3031356T3 (en) 2000-01-31
BR9408506A (pt) 1997-08-05
AU8066394A (en) 1995-08-15
RU2126404C1 (ru) 1999-02-20
FI950403A0 (fi) 1995-01-30
HUT75942A (en) 1997-05-28
JPH09501698A (ja) 1997-02-18
PL179448B1 (pl) 2000-09-29
CA2182101A1 (en) 1995-08-03
CA2182101C (en) 1999-08-03
EG20672A (en) 1999-11-30
FI113769B (fi) 2004-06-15
AU684568B2 (en) 1997-12-18
HU221633B1 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
NO952890D0 (no) Kombinasjonsbehandling for inhibisjon av bentap
DE69420053D1 (de) Neuroprotektive chroman verbindungen
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
NO20012310D0 (no) Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
EP0653936A1 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs.
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
FR2718965B1 (fr) Nouvelle application thérapeutique de la spiramycine.
BG105289A (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee